title: [How should we use the short-acting insulin analog Lys-Pro in external continuous subcutaneous pumps?].
abstract: External pump treatment improves glycemic control, particularly thanks to the continuous basal rate. The pharmacokinetics of the short-acting insulin analog lispro allow a better control of post-prandial hyperglycemia than regular insulin. The use of the short-acting insulin analog in the pump improves HbA1c and blood glucose stability, without increasing the risk of hypoglycemia. Frequent blood glucose self-monitoring is required in order to optimize insulin adjustments, using the retro-active method. Systematic monitoring of urine ketones is also required, for an early detection of any interruption in insulin delivery. Under these conditions, this modality of intensified treatment seems very efficient.
authors.affiliation: Service de Diabétologie, Maladies Métaboliques et Maladies de la Nutrition, Hôpital Jeanne d'Arc, CHU de Nancy, 54201 Toul Cedex, B.P. 303, France.
authors.forename: B
authors.initials: B
authors.lastname: Guerci
authors.forename: N
authors.initials: N
authors.lastname: Jeandidier
authors.forename: V
authors.initials: V
authors.lastname: Lassmann-Vague
authors.forename: E
authors.initials: E
authors.lastname: Renard
authors.forename: H
authors.initials: H
authors.lastname: Hanaire-Broutin
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D015190:Blood Glucose Self-Monitoring; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D007332:Insulin Infusion Systems; D061268:Insulin Lispro
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro